250 related articles for article (PubMed ID: 26454938)
1. [Effectiveness and safety of antiviral therapy of military personnel suffering from chronic hepatitis C].
Zhdanov KV; Gusev DA; Kozlov KV; Shishkin MK; Sukachev VS; Shakhmanov DM; Zhabrov SS
Voen Med Zh; 2015 Apr; 336(4):44-9. PubMed ID: 26454938
[TBL] [Abstract][Full Text] [Related]
2. A preliminary study on the efficacy and influencing factors of interferon for the treatment of genotype 1 chronic hepatitis C with different dosage forms.
Ma P; Yang JM; Hou W; Song SD; Wang L; Lu W
Eur J Gastroenterol Hepatol; 2013 May; 25(5):601-5. PubMed ID: 23263720
[TBL] [Abstract][Full Text] [Related]
3. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
Ann Intern Med; 2013 Dec; 159(11):I-14. PubMed ID: 24297207
[No Abstract] [Full Text] [Related]
4. [Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases].
Lopukhova NL
Eksp Klin Gastroenterol; 2007; (4):146-52. PubMed ID: 18409502
[No Abstract] [Full Text] [Related]
5. Therapy of chronic hepatitis C with PEG-IFN α-2b plus ribavirin in patients with genotype 2 or 3: 16 versus 24 weeks, clinical outcome and direct cost analyses.
Fabris P; Carlotto A; Del Bianco T; Malfatti F; Tramarin A; Miotti MA; Baldo V; Floreani A; Giordani MT; Grasso A
Eur J Gastroenterol Hepatol; 2013 Dec; 25(12):1396-401. PubMed ID: 23743559
[TBL] [Abstract][Full Text] [Related]
6. Ribavirin in chronic hepatitis C: past and future.
Loustaud-Ratti V; Rousseau A; Marquet P; Denis F; Alain S
Expert Rev Anti Infect Ther; 2009 Apr; 7(3):249-53. PubMed ID: 19344238
[No Abstract] [Full Text] [Related]
7. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F
Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of peginterferon α-2a (40 KD) plus ribavirin in treatment-naive chronic hepatitis C patients in Central and Eastern Europe.
Urbanek P; Oltman M; Ivanovski L; Rehák V; Messinger D; Tietz A; Husa P
Eur J Gastroenterol Hepatol; 2011 Nov; 23(11):1004-10. PubMed ID: 21904204
[TBL] [Abstract][Full Text] [Related]
9. [Pegylated-interferon alpha plus ribavirin-induced subacute thyroiditis in chronic hepatitis C].
Abellán Galiana P; Pérez-Lázaro A; Aguilera Sancho-Tello V; Merino Torres JF; Berenguer Haym M; Piñón Sellés F
Endocrinol Nutr; 2009 Mar; 56(3):136-9. PubMed ID: 19627727
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of daclatasvir with peginterferon alfa-2b and ribavirin for HCV genotype 1 infection.
Suzuki F; Toyota J; Ikeda K; Chayama K; Mochida S; Hayashi N; Ishikawa H; Miyagoshi H; Hu W; McPhee F; Hughes EA; Kumada H
Antivir Ther; 2014; 19(5):491-9. PubMed ID: 24451122
[TBL] [Abstract][Full Text] [Related]
11. Retinal vein thrombosis associated with peginterferon alpha 2b plus ribavirin in a chronic hepatitis C patient.
Such Díaz A; Barrueco N; Esteban Alba C; Escobar Rodríguez I
Farm Hosp; 2011; 35(2):93-4. PubMed ID: 20615736
[No Abstract] [Full Text] [Related]
12. Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-α for the treatment of chronic hepatitis C in HIV-infected patients: the PERICO trial.
Labarga P; Barreiro P; da Silva A; Guardiola JM; Rubio R; Aguirrebengoa K; Miralles P; Portu J; Téllez MJ; Morano L; Castro A; Pineda JA; Terrón A; Hernández-Quero J; Mariño A; Ríos MJ; Echeverría S; Asensi V; Vispo E; Soriano V;
J Infect Dis; 2012 Sep; 206(6):961-8. PubMed ID: 22807523
[TBL] [Abstract][Full Text] [Related]
13. Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial.
Liu CH; Liu CJ; Huang CF; Lin JW; Dai CY; Liang CC; Huang JF; Hung PH; Tsai HB; Tsai MK; Lee CY; Chen SI; Yang SS; Su TH; Yang HC; Chen PJ; Chen DS; Chuang WL; Yu ML; Kao JH
Gut; 2015 Feb; 64(2):303-11. PubMed ID: 24747867
[TBL] [Abstract][Full Text] [Related]
14. [Simeprevir in combination with pegylated interferon-α and ribavirin in the treatment of naïve patients with genotype 1 chronic hepatitis C].
Burnevich EZ
Ter Arkh; 2014; 86(11):105-14. PubMed ID: 25715498
[TBL] [Abstract][Full Text] [Related]
15. [Therapy of chronic hepatitis C].
Schaffstein S; Rampini SK; Müllhaupt B
Praxis (Bern 1994); 2014 Apr; 103(8):423-36. PubMed ID: 24713377
[No Abstract] [Full Text] [Related]
16. Pegylated IFN-α-2a and ribavirin in the treatment of hepatitis C infection in children.
Pawlowska M
Expert Opin Drug Saf; 2015 Mar; 14(3):343-8. PubMed ID: 25599750
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.
Ogawa E; Furusyo N; Kajiwara E; Takahashi K; Nomura H; Tanabe Y; Satoh T; Maruyama T; Nakamuta M; Kotoh K; Azuma K; Dohmen K; Shimoda S; Hayashi J;
J Gastroenterol Hepatol; 2012 Jul; 27(7):1233-40. PubMed ID: 22098185
[TBL] [Abstract][Full Text] [Related]
18. [Effect of interferon and ribavirin combination therapy in sixty-two patients with chronic hepatitis C originating from a single blood donor].
Liu SD; Cheng ML; Ren H; Yang QK; Shu DY
Zhonghua Gan Zang Bing Za Zhi; 2012 Aug; 20(8):589-92. PubMed ID: 23207152
[TBL] [Abstract][Full Text] [Related]
19. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
Dore GJ; Lawitz E; Hézode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Tran A; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey D; Pol S; Harley H; George J; Fung SK; de Lédinghen V; Hagens P; McPhee F; Hernandez D; Cohen D; Cooney E; Noviello S; Hughes EA
Gastroenterology; 2015 Feb; 148(2):355-366.e1. PubMed ID: 25311593
[TBL] [Abstract][Full Text] [Related]
20. The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.
Manns MP; Vierling JM; Bacon BR; Bruno S; Shibolet O; Baruch Y; Marcellin P; Caro L; Howe AY; Fandozzi C; Gress J; Gilbert CL; Shaw PM; Cooreman MP; Robertson MN; Hwang P; Dutko FJ; Wahl J; Mobashery N
Gastroenterology; 2014 Aug; 147(2):366-76.e6. PubMed ID: 24727022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]